A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
Launched by ANDERSON CLINICAL RESEARCH · Aug 30, 2001
Trial Information
Current as of July 15, 2025
Completed
Keywords
ClinConnect Summary
Patients receive open-label ALRT1057 for 16 weeks, as tolerated. In the absence of unacceptable toxicity, patients may continue treatment indefinitely provided they continue to benefit from therapy and the study remains open and active.
Thirteen patients are treated initially. If at least one response is observed in these patients, up to 14 additional patients will be evaluated.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV positive status and histologic confirmation of KS.
- • CD4 count \> 200 mm3 (required of one-half of patients).
- • Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions.
- • Acceptable organ system function.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- • Serious or intercurrent illness or infection that would interfere with the ability of the patient to carry out the treatment program.
- Prior Medication:
- Excluded:
- • Systemic therapy for KS within 30 days.
- • Local or topical therapy for KS indicative lesions within 60 days.
- • Systemic therapy with vitamin A in doses exceeding 15,000 IU per day or other retinoid class drug.
- Required:
- • Approved antiretroviral therapy.
About Anderson Clinical Research
Anderson Clinical Research is a dedicated clinical trial sponsor committed to advancing medical science through rigorous and innovative research practices. With a focus on enhancing patient outcomes, the organization collaborates with healthcare professionals, research institutions, and regulatory bodies to conduct high-quality clinical trials across various therapeutic areas. Leveraging a team of experienced researchers and state-of-the-art facilities, Anderson Clinical Research prioritizes patient safety and ethical standards while striving to bring new treatments and therapies to market efficiently and effectively. Through its commitment to excellence, the organization plays a vital role in the development of groundbreaking medical solutions that address unmet healthcare needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials